Ratings Nanexa AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-20 EDT			5-day change	1st Jan Change
0.894 ^SEK	+1.13%		-4.49%	-27.32%

06-11	Nanexa AB Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes	CI
05-15	Nanexa AB Elects Hanna Tilus as Members of the Board	CI

Thanks to a sound financial situation, the firm has significant leeway for investment.
With regards to fundamentals, the enterprise value to sales ratio is at 0.78 for the current period. Therefore, the company is undervalued.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NANEXA AB	-27.32%	11.59M		-
SEDANA MEDICAL AB	+4.49%	230M		C-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality